CN103180342A - 用于治疗hiv的抗体 - Google Patents

用于治疗hiv的抗体 Download PDF

Info

Publication number
CN103180342A
CN103180342A CN2011800520640A CN201180052064A CN103180342A CN 103180342 A CN103180342 A CN 103180342A CN 2011800520640 A CN2011800520640 A CN 2011800520640A CN 201180052064 A CN201180052064 A CN 201180052064A CN 103180342 A CN103180342 A CN 103180342A
Authority
CN
China
Prior art keywords
antibody
hiv
cdr
seq
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800520640A
Other languages
English (en)
Chinese (zh)
Inventor
C·克林格-汉默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/913,300 external-priority patent/US9090686B2/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN103180342A publication Critical patent/CN103180342A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2011800520640A 2010-10-27 2011-10-27 用于治疗hiv的抗体 Pending CN103180342A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
US12/913,300 2010-10-27
PCT/EP2011/068905 WO2012055980A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
CN103180342A true CN103180342A (zh) 2013-06-26

Family

ID=44913256

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800520640A Pending CN103180342A (zh) 2010-10-27 2011-10-27 用于治疗hiv的抗体

Country Status (10)

Country Link
EP (1) EP2632953A1 (enExample)
JP (1) JP2014504147A (enExample)
KR (1) KR20140009174A (enExample)
CN (1) CN103180342A (enExample)
AU (1) AU2011322508A1 (enExample)
CA (1) CA2814908A1 (enExample)
MX (1) MX2013004710A (enExample)
RU (1) RU2013122770A (enExample)
WO (1) WO2012055980A1 (enExample)
ZA (1) ZA201302639B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105980405A (zh) * 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961427B1 (en) * 2013-02-28 2020-03-25 Gnvie, Llc Hiv antigens and antibodies
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
CN102459343A (zh) * 2009-04-29 2012-05-16 皮埃尔法布雷医药公司 用于治疗hiv的抗cxcr4抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
CN102459343A (zh) * 2009-04-29 2012-05-16 皮埃尔法布雷医药公司 用于治疗hiv的抗cxcr4抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STRIZKI J M ET AL: "A monoclonal antibody（12G5） directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1（89.6） but not the T-tropic isolate HIV-1（HxB）", 《JOURNAL OF VIROLOGY》 *
TANAKA R ET AL: "Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection", 《JOURNAL OF VIROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105980405A (zh) * 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途

Also Published As

Publication number Publication date
AU2011322508A1 (en) 2013-05-02
MX2013004710A (es) 2013-08-29
KR20140009174A (ko) 2014-01-22
EP2632953A1 (en) 2013-09-04
ZA201302639B (en) 2013-11-27
JP2014504147A (ja) 2014-02-20
CA2814908A1 (en) 2012-05-03
WO2012055980A1 (en) 2012-05-03
RU2013122770A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
CN102459343B (zh) 用于治疗hiv的抗cxcr4抗体
US12234286B2 (en) Anti-TIGIT antibodies and their use as therapeutics and diagnostics
JP7610302B2 (ja) Ｃｃｒ８抗体及びその用途
JP6936361B2 (ja) ヒト免疫不全ウイルス中和抗体
KR20210028223A (ko) HIV gp120을 표적화하는 항체 및 사용 방법
KR102678252B1 (ko) 재조합 이중특이적 항체
CN117751143A (zh) 抗pvrig/抗tigit双特异性抗体和应用
TWI764291B (zh) 抗tigit抗體及使用方法
CN113164777A (zh) Csf1r/ccr2多特异性抗体
KR20230137948A (ko) Cd19 및 cd22에 결합하는 이중특이적 키메라 항원 수용체
CN103180342A (zh) 用于治疗hiv的抗体
HK1182725A (en) Antibodies for the treatment of hiv
HK1165813B (en) Anti cxcr4 antibodies for the treatment of hiv
WO2021175954A1 (en) Antibodies having specificity for btnl8 and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182725

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130626

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1182725

Country of ref document: HK